Effects of Lipochromin and Levosinum in the modulation of radiation-induced injury to pig skin

• Published in: British journal of radiology Vol. 73; no. 871; pp. 771 - 775
• Main Authors: Rezvani, M, Uzlenkova, N, Whitehouse, E, Frenkel, L, Wilkinson, J H, Ross, G, Morris, G M, Hopewell, J W, Pilipenko, N
• Format: Journal Article
• Language: English
• Published: England 01-07-2000
• Subjects: Administration, Cutaneous; Animals; Anticarcinogenic Agents - administration & dosage; Carotenoids - administration & dosage; Drug Combinations; Models, Animal; Necrosis; Ointments; Radiation Injuries, Experimental - drug therapy; Radiation-Protective Agents - administration & dosage; Skin - drug effects; Skin - radiation effects; Swine; Time Factors
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr.73.871.11089470

Pig skin was used as a model to study the effectiveness of two topically applied creams, Lipochromin and Levosinum, in modifying the development of both early and late radiation damage to pig skin. Irradiated skin sites that received daily topical application of Levosinum or Lipochromin after exposure were compared with sites on the contralateral flank of the same animal that received irradiation only. Irradiation was with graded doses of 90Sr/90Y beta-rays. Incidence of moist desquamation (acute) and ischaemic dermal necrosis (late) were used as end-points. The latency period for the development of moist desquamation and its healing time was also assessed. The latency period for the development of moist desquamation in this model ranged from 4.00-6.75 weeks. There was no significant difference between the cream treatment and control sites. Application of Levosinum shortened the healing time of moist desquamation at each dose level by 5-10 days. In three out of four dose levels used, this shortening of the healing time was statistically significant (p < 0.03). Treatment with these topical applications also reduced the incidence of late dermal necrosis and increased the ED50 values for the incidence of dermal necrosis. This increase in ED50 values was equivalent to a dose modification factor of 1.11-1.13.